BioSpace News Archive

Arcutis Biotherapeutics, Inc. announced that ZORYVE® cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on CVS Caremark’s largest national commercial formularies effective July 5.

Madrigal Pharmaceuticals, Inc. announced the completion of the rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for resmetirom for the treatment of adults with NASH with liver fibrosis, a disease with no approved therapy.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio execution.

IceCure Medical Ltd. announced it has entered a non-exclusive distribution agreement with Medicinália Cormédica – MC Medical, Lda., the largest distributor of third-party medical devices in Portugal and a subsidiary of Barcelona, Spain based Werfen, S.A., a world leader in specialized diagnostics operating in 30 countries.

Astria Therapeutics, Inc. today announced that it has named John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations.

Enveric Biosciences today announced positive results from PK animal studies demonstrating oral bioavailability, rapid onset of action and systemic clearance, and a more favorable side effect profile for the company’s lead product candidate, EB-373.

To extend the benefits of genomic testing research for reproductive health labs, Thermo Fisher Scientific today launched two new next-generation sequencing-based options to support preimplantation genetic testing-aneuploidy (PGT-A) used commonly to inform in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research.

Janux Therapeutics, Inc. today announced interim Phase 1 clinical data for PSMA-TRACTr JANX007 in adult subjects with metastatic castration-resistant prostate cancer (mCRPC) and provided a pipeline update.

NeuroSense Therapeutics Ltd. today announced it will host an investor conference at its U.S. office in Cambridge, Massachusetts on Monday, July 24, 2023 from 8:30 AM- 10:15 AM.

IRLAB Therapeutics AB announced that the independent Data and Safety Monitoring Board for the ongoing Phase IIb study with pirepemat, after review of safety and the integrity of data, unanimously recommends that the Phase IIb study continues.